Inhibikase Therapeutics股价在定价1.1亿美元的私募股权后上涨

2024-10-09 22:16

Inhibikase Therapeutics (NASDAQ:IKT) on Wednesday has announced the pricing of an approximately $110M private offering, led by new investor Soleus Capital.
The pharma company intends to use the net proceeds from the private placement to finance the initiation of a Phase 2b trial in pulmonary arterial hypertension and for general corporate purposes.
The company is selling 58.31M shares of its common stock and, in lieu of common stock to certain investors, pre-funded warrants to purchase up to 21,985,000 shares, along with accompanying Series A-1 warrants to purchase over 40.13M and accompanying Series B-1 warrants to purchase over 73.81M shares.
The purchase price for each share of common stock and accompanying warrants is $1.37 (provided, the purchase price for each pre-funded warrant and accompanying warrants is $1.369).
The Series A-1 warrants have an exercise price of $1.37 per share, and the Series B-1 warrants have an exercise price of $1.49 per share.
The private placement is expected to close on October 21, 2024.
IKT shares jumped over 30% at market open on Wednesday.
Source: Press Release

More on Inhibikase Therapeutics